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Abstract
Background: The worldwide burden of stillbirths is large, with an estimated 2.6 million babies stillborn in 2015 including
1.3 million dying during labour. The Every Newborn Action Plan set a stillbirth target of ≤12 per 1000 in all countries by
2030. Planning tools will be essential as countries set policy and plan investment to scale up interventions to meet this
target. This paper summarises the approach taken for modelling the impact of scaling-up health interventions on
stillbirths in the Lives Saved tool (LiST), and potential future refinements.
Methods: The specific application to stillbirths of the general method for modelling the impact of interventions in LiST
is described. The evidence for the effectiveness of potential interventions to reduce stillbirths are reviewed and the
assumptions of the affected fraction of stillbirths who could potentially benefit from these interventions are presented.
The current assumptions and their effects on stillbirth reduction are described and potential future improvements
discussed.
Results: High quality evidence are not available for all parameters in the LiST stillbirth model. Cause-specific
mortality data is not available for stillbirths, therefore stillbirths are modelled in LiST using an attributable
fraction approach by timing of stillbirths (antepartum/ intrapartum). Of 35 potential interventions to reduce
stillbirths identified, eight interventions are currently modelled in LiST. These include childbirth care, induction for
prolonged pregnancy, multiple micronutrient and balanced energy supplementation, malaria prevention and
detection and management of hypertensive disorders of pregnancy, diabetes and syphilis. For three of the
interventions, childbirth care, detection and management of hypertensive disorders of pregnancy, and diabetes the
estimate of effectiveness is based on expert opinion through a Delphi process. Only for malaria is coverage
information available, with coverage estimated using expert opinion for all other interventions. Going forward,
potential improvements identified include improving of effectiveness and coverage estimates for included
interventions and addition of further interventions.
Conclusions: Known effective interventions have the potential to reduce stillbirths and can be modelled using the
LiST tool. Data for stillbirths are improving. Going forward the LiST tool should seek, where possible, to incorporate
these improving data, and to continually be refined to provide an increasingly reliable tool for policy and
programming purposes.
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Background
The worldwide burden of stillbirths is large, with an esti-
mated 2.6 million babies stillborn in 2015 including 1.3
million dying during labour [1]. Stillbirths are an import-
ant marker both of maternal health, but also of access to
high quality care in pregnancy and particularly around
the time of birth [1–3]. These two factors provide an ex-
planation for much of the differences observed in still-
birth rates worldwide, and have received much interest
in global health [2–5]. However, despite the large burden
and these links to maternal health and quality of care,
stillbirths are not included in routine global monitoring
[1, 6]. Failure to count stillbirths ignores their impact on
women, families and society, underestimates the benefits
of investments in maternity care, and has led to failure
of investment to reduce stillbirth numbers [5, 7, 8].
Some evidence of increased recognition of the import-
ance of stillbirths on a global level has been seen
recently with stillbirths included in the 2014 Every New-
born Action Plan (ENAP) to end preventable deaths of
newborns, mothers and stillbirths, and as a core indica-
tor in the Global Strategy on Women’s Children’s and
Adolescent Health [9, 10]. Improved stillbirth data
collection will be essential to allow tracking of progress
towards the ENAP stillbirth target of ≤12 per 1000 by
2030, and Global Strategy tracking of the stillbirth and
linked indicators for the Sustainable Development Goals
3.1 and 3.2. However, in addition to these improved
data, tools such as the Lives Saved Tool will be essential
to help countries set policy and plan investment to scale
up interventions to meet the national ENAP stillbirth
target.
The Lives Saved Tool (LiST) is an evidence-based soft-
ware tool used to model the impact of scaling-up health
interventions aimed to reduce mortality and morbidity
in mothers, newborns, and children under five years of
age and stillbirths. The framework has continued to
evolve since the original Lancet 2003 child survival series
examined the impact of increasing coverage of proven
child health interventions, and the model has expanded
to include further interventions and outcomes as the
need for such a tool to help guide policy and program
planning became evident [11, 12]. LiST has been
adopted by diverse stakeholders, and can be integrated
into and strengthen existing planning processes.
Stillbirths were added as an outcome to the LiST
model in 2011. The 2011 supplement in BMC Public
Health published 7 papers on the impact of interventions
on the risk of stillbirth for pregnant women [13–19], and
an overview of the modelling approach was included in
the original Lancet Stillbirth Series [20]. The interventions
included in these publications describe the scientific
underpinning of the LiST-based estimates for stillbirth re-
duction reported in the Lancet Stillbirth Series 2011,
Lancet Every Newborn Series in 2014 and Lancet Ending
Preventable Stillbirths Series 2016 [8, 21, 22]. However,
the modelling of stillbirths has evolved during this period,
in response to the changing evidence landscape with the
suite of interventions modelled varying over time. In this
paper we present an overview of the currently included in-
terventions, data inputs and assumptions underlying the
existing LiST model for the impact of scaling-up health
interventions on stillbirths. Where relevant, details about
changes which have occurred over time and potential re-
finements for future versions are presented.
Methods
Theoretical approach and basic modelling structure of
LiST
The modelling structure and underlying theory of change
of the LiST model has been described in detail in previous
publications [23]. Briefly, LiST is a linear, mathematical
deterministic model with fixed relationships between in-
puts (coverage of interventions) and outputs (changes in
cause-specific mortality or population-level risk factors for
mortality such as intrauterine growth restriction (IUGR))
[24]. Its framework is based upon demographic details,
cause of death information, coverage indicators and inter-
vention effectiveness estimates (Table 1). It assumes that
mortality rates and the cause of death structure will not
change dynamically, and that any differences in the out-
comes will be attributable to the change in coverage of
key interventions.
LiST allows users to set up and run multiple sce-
narios, called projections, in order to estimate the im-
pact of different health intervention packages based
upon coverage at the national or subnational (e.g.
region, state, or district) level. These projections
provide a structured format for program managers or
ministry of health personnel to utilize the latest
scientific information about the effectiveness of inter-
ventions for maternal, neonatal, and child health;
combine information about causes of death and
current coverage of interventions to inform planning
and decision-making, and help prioritize investments
and evaluate existing programs. Currently, there are
approximately 60 interventions amenable to scale-up in
low and middle income settings in the short to medium
term that are categorized across the continuum of care
which impact mortality and morbidity outcomes for
specific population subgroups (e.g. stillbirths, neonatal,
child-under 5, or maternal deaths) or risk factors (e.g.
stunting and wasting) modelled in LiST.
Work to review and estimate the cause-specific effects
for interventions was previously led by the Child Health
Epidemiology Reference Group (CHERG) of the World
Health Organization (WHO) and UNICEF following
established standard practices and guidelines using an
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adapted GRADE approach [25]. Consistent with this
approach, where evidence from trials or observational
studies were not available for a given intervention, an
expert Delphi process was undertaken to determine an
effect estimate. Data from low and middle income set-
tings were used where possible. Baseline coverage data
were based on the latest nationally representative house-
hold surveys where available and where such data were
not available, expert opinion from the neonatal and still-
birth leads (ZB and JEL) was used to estimate coverage.
Oversight and recommendations continue to be led by
global health experts organized into technical working
groups around a specific area of expertise (e.g. nutrition)
which meet on an ad hoc basis to highlight areas for
future work and refinements to strengthen the model.
Implementation of changes and overall development of
the LiST model continues to be led and managed by the
Institute for International Programs at the Johns
Hopkins Bloomberg School of Public Health.
Modelling stillbirths in LiST
Special considerations exist when modelling stillbirths
in LiST compared to other maternal-child outcomes,
in large part due to lack of reliable and routinely
collected data related to stillbirths in many data plat-
forms. Stillbirths are modelled independently in LiST
compared to other maternal-child outcomes. The
overall envelope for the estimated total number of
stillbirths at ≥1000 g or ≥28 weeks (third trimester or
late fetal deaths) in a country are obtained from
WHO estimates [26]. However, in contrast to many
other maternal-child outcomes, standard definitions of
stillbirth are not universally applied across interven-
tion studies. Hence, it is sometimes necessary to as-
sume that the reductions in mortality for specific
interventions that have been reported using a wider
definition, e.g. fetal deaths ≥22 weeks or even ‘all fetal
losses regardless of gestation’, would also apply to
stillbirths at ≥28 weeks.
In addition, systematic estimates of cause of death for
stillbirths are not available, therefore stillbirths are mod-
elled using a simple classification based upon timing of
stillbirth – antepartum (prior to the onset of labour) or
intrapartum (fetal death during labour, but prior to full
extraction from the mother). Whilst this is commonly
used from a programmatic perspective, even the under-
lying data to produce country-level estimates according
to this dichotomy of stillbirth timing are very sparse,
with estimates of the proportion of stillbirths that are
intrapartum being based upon a regional median ap-
proach for most countries [1] .
Therefore, whereas for maternal deaths, and child
deaths following a livebirth, estimates of efficacy or effect-
iveness to reduce cause-specific mortality (rather than
overall mortality) can be used, this is not possible for still-
births. Stillbirths lack cause of death information and
therefore, neither estimates for the envelope of the num-
ber of stillbirths from a specific cause, or intervention-
based cause-specific mortality changes can be estimated.
An overview of the modelling approach for still-
births in LiST is shown in Fig. 1. Any given interven-
tion can have an effect on antepartum or intrapartum
stillbirths, or both. The effectiveness of the interven-
tion is derived based on published evidence. Where
no published evidence is available for an intervention,
the estimate of effectiveness is obtained through
expert opinion (see below for specific details). In LiST
to calculate the number of stillbirths averted, the
estimate of effectiveness is multiplied by the change
in coverage. For example, if syphilis detection and
treatment is 82% effective in reducing antepartum
stillbirths attributable to syphilis, but none of a given
population has access to this intervention at baseline,
an increase in coverage to 50% is estimated to avert:
82% X (50%–0%) = 41% of all antepartum stillbirths
attributable to syphilis.
Some interventions have limited effectiveness so mod-
elled impact is restricted to a sub-group of all deaths. This
Table 1 Framework of the Lives Saved Tool
Parameter of the Lives Saved Tool Source of Data
Demography details (e.g. total population, fertility) Demographic projections produced by the United Nations Population Division
or derived from national or subnational demographic estimates
Cause of death information from country-specific WHO profiles or
estimated by using local data sources
Country-specific profiles produced by Maternal and Child Epidemiology
Estimation (MCEE) group or estimated based upon local data sources
Coverage levels for a variety of key health interventions that affect
child and maternal mortality
Nationally representative household surveys, such as Demographic and
Health Surveys (DHS) and Multiple Indicator Cluster Surveys (MICS), or
local data sources (e.g. annual state surveys or program data)
Health status indicators for a national or subnational setting Nationally representative household surveys, such as Demographic and
Health Surveys (DHS) and Multiple Indicator Cluster Surveys (MICS), or
local data sources (e.g. annual state surveys or program data)
Effectiveness estimates for stillbirth, maternal, neonatal, and child
interventions
Cochrane reviews, meta-analyses, Delphi studies, and scientific literature
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‘affected fraction’ is defined in LiST as the proportion of
the cause-specific mortality, here antepartum or intrapar-
tum stillbirths, that is considered susceptible to that inter-
vention. Where possible this is calculated as the
intrapartum or antepartum stillbirths attributable to the
underlying cause in the population based on the
prevalence of the risk factor and the increased risk of still-
birth among women exposed to the risk factor (see
Additional file 1). If an estimate of increased stillbirth risk
is not known for any risk factor, the risk of stillbirth re-
mains the same in those with the exposure as the general
population, and hence will underestimate the affected
fraction.
For example, balanced energy supplementation has
evidence of a 40% reduction in antepartum stillbirths in
food-insecure households, but no effect on stillbirths in
other households. The number of stillbirths averted is
calculated as the estimate of effectiveness multiplied by
the coverage multiplied by the ‘affected fraction’. If 20%
of a population are food insecure and the coverage was
increased from 0 to 50% of food insecure households the
estimated number of stillbirths averted would be: 40% X
(50%–0%) X 20% = 4% of all antepartum stillbirths.
Interventions to reduce stillbirths
As a first step in defining potential interventions to re-
duce stillbirths, a conceptual framework of previously
identified risk factors for stillbirths can be used (Fig. 2)
[1, 27–29]. It should be noted that many of the pathways
to stillbirth, particularly antepartum stillbirths, remain
inadequately understood, however, for the purposes of
this work we are interested in currently modifiable
factors. Based on this conceptual framework, a list of po-
tential interventions along the continuum of care from
preconception through childbirth care to address these
factors, and hence reduce stillbirth mortality, can be
considered. Potential interventions of interest were se-
lected on the basis of clear or potential evidence of
benefit to reduce stillbirth. Interventions relevant to
public health policy, such as those with a large impact
on stillbirth reduction that are amenable to scale-up in
low and middle income settings in the short to medium
term are prioritised. The LiST model currently includes
a total of eight interventions that have an impact on
stillbirth mortality (Fig. 3). The included interventions
have been revised over time (Table 2).
Results
Summary of included interventions to reduce stillbirth
Of the many possible modifiable underlying causes and
risk factors for stillbirth, evidence of scale-able interven-
tions with potential public health effect are only avail-
able for a subset. Systematic reviews undertaken prior to
the inclusion of stillbirths in LiST in 2011 identified 35
potential interventions, of which 10 were strongly rec-
ommended by the technical working group for inclusion
in LiST. Since that time two interventions, folic acid
supplementation and fetal growth restriction detection
and management have been removed, and two new nu-
tritional interventions have been added. Table 2 contains
a summary of the interventions modelled within LiST,
including the dates that these were included in or
removed from the model. Details of the sources of esti-
mates of intervention effects, affected fraction and
Fig. 1 Overview of modelling approach for stillbirths in the Lives Saved Tool
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coverage are provided in Table 3 and Additional file 1,
with details described below for each intervention.
Further details about the quality of the evidence of effect-
iveness for the included interventions can be found in
Additional file 2. More detailed descriptions of the cur-
rently included interventions are provided below:
Preventative interventions before and during pregnancy
Supplementation with micronutrients before and during
pregnancy
Micronutrient deficiencies are common amongst preg-
nant women and are associated with fetal growth restric-
tion and congenital abnormalities, which can both
increase the risk of stillbirth.
Haider et al. found a 9% reduction in all-cause stillbirths
with micronutrient supplementation during pregnancy
compared to iron with or without folic acid (15 RCTs
n = 98,808 RR = 0.92, 95% CI 0.86 to 0.99) [30]. Folic acid
has previously been shown to have a protective effect to
reduce neural tube defects, which are associated with an
increased risk of stillbirths, especially when severe [31].
Up until 2016, the effect of folic acid was included in the
LiST model for stillbirths (see Additional file 2). This as-
sumed that fortification and supplementation with folic
acid were interchangeable. However, whilst the evidence
for the effect of folic acid fortification is increasing [32],
there is currently no evidence to support an effect of folic
acid supplementation, which requires starting peri-
conceptually, on all-cause stillbirth mortality (4 trials
(n = 6597) RR = 1.05 (95% CI 0.54 to 2.05) and therefore
the intervention was removed from the LiST model [33] .
No evidence of an effect of Vitamin A, C, D or E, or
zinc, magnesium or calcium supplementation on stillbirth
reduction has been found in recent Cochrane reviews
[34–40], and only the effect for micronutrient supplemen-
tation is currently included in the LiST model for
Fig. 3 Interventions included in Lives Saved Tool model which impact on stillbirths by timing (antepartum/ intrapartum). This schema represents
the LiST modelling of stillbirths as of September 2016
Fig. 2 Conceptual framework for known pathways to stillbirth. *This conceptual framework focuses on known conditions in pregnancy associated
with stillbirth and understood pathways to stillbirth which are potentially amenable to interventions. The underlying causes and factors in many
stillbirths remain unknown, this framework should be revised as further evidence becomes available
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stillbirths (see footnote Table 2). The estimate of effect for
micronutrient supplementation is for all pregnant women,
and hence the affected fraction is 1.0 for both antepartum
and intrapartum stillbirths. As coverage of micronutrient
supplementation during pregnancy is generally very
low, the default for baseline coverage of this interven-
tion in LiST is 0% in all settings (Table 2). It should
be noted that in all these micronutrient studies, the
number of included cases is relatively low, and as
such they may have been under-powered to detect a
true effect, especially if the effect size or the affected
fraction (on which the intervention may have an ef-
fect) is small. However, in these cases, it is less likely
that increasing coverage of these interventions at a
population level would have a substantial impact on
stillbirths in a country.
Balanced energy supplementation
Maternal undernutrition is associated with poor fetal
growth, low birthweight, and increased risk of stillbirth
[41]. Balanced energy supplementation was found to re-
duce all-cause stillbirths by 40% in food-insecure house-
holds (5 RCTs 3408 women. (RR 0.60, 95% CI 0.39 to
0.94)) [42]. The proportion of the population living on
<$1.90/day from World Bank is used as the affected
fraction, to approximate food-insecure households [43].
It is assumed that this proportion is equal to the propor-
tion of stillbirths occurring in food-insecure households,
i.e. that the stillbirth rate in food-insecure is the same as
that in insecure households. This is likely to be a
conservative estimate, as stillbirth rates may be higher in
food-insecure households, where other risk factors for
stillbirths are likely to co-exist. It is assumed that the
baseline coverage in LiST for this intervention is 0% in
all settings.
Prevention of malaria in pregnancy
It is estimated that over 125 million pregnant women
are at risk of malaria each year, with pregnant women at
risk of more severe disease, and their fetus is vulnerable
due to effects of maternal systemic febrile illness, im-
paired placenta function due to placental infection, or
the more rare condition of direct fetal infection [44].
Malaria is hence an important cause of stillbirth in
countries where malaria is endemic, and is estimated to
be attributable for around 20% of stillbirths in sub-Sa-
haran Africa. There is moderate evidence of the effect-
iveness of insecticide-treated bednets (ITNs) to reduce
all-cause fetal loss (stillbirths and miscarriages at all ges-
tational ages) for women during their first and second
pregnancies (3 cRCTs (RR 0.67, 95% CI 0.47 to 0.97))
[18, 45]. No significant effect of intermittent
preventative treatment in pregnancy (IPTp) to prevent
all-cause stillbirths was found in a recent Cochrane re-
view (5 RCTs, 7130 women. RR 1.02, 95% CI 0.76 to
1.36. Moderate quality evidence) [46] .
In LiST, the affected fraction to which this effect
estimate is currently applied represents stillbirths at-
tributable to falciparum malaria. Although initially it
was planned that impact would be calculated assum-
ing that only women in their 1st or 2nd pregnancies
were at increased risk of stillbirth, currently the
estimate includes stillbirths attributable to malaria
Table 2 Summary of interventions effecting stillbirths included in the Lives Saved Tool 2011–2016 a
Period Intervention Antepartum Stillbirths Intrapartum Stillbirths Current status
Periconceptual Folic acid supplementation/ Fortification X X Not included. Included in previous versions
to Feb 2016
Pregnancy Multiple micronutrient supplementation X X New intervention added in Feb 2016b
Pregnancy Malaria prevention with ITp or ITNc X Included since 2011
Pregnancy Balanced energy supplementation X X New intervention added in Feb 2016
Pregnancy Syphilis detection and treatment X Included since 2011
Pregnancy Diabetes case management X X Included since 2011
Pregnancy Management of hypertensive disorders
of pregnancy
X X Included since 2011
Pregnancy Fetal growth restriction detection and
management
X X Not included. Included in previous versions
to May 2015
Childbirth Labour and delivery management X Included since 2011
Childbirth Induction of labour for pregnancies
lasting >41 weeks
X X Included since 2011
aThe LiST model continues to evolve, hence some interventions have been added since 2011, and others have been removed as the knowledge base changes.
The final column provides details of the current status in version 5.45 (Sept 20 2016)
bNew evidence from the updated Cochrane suggests that there is no effect of multiple micronutrient supplementation on stillbirths (RR 0.97, 95% CI 0.87–1.09)
and this effect and it is likely that the technical working group will recommend that the effect is removed in subsequent LiST revisions
cIntervention is labelled as IPTp (Intermittent prophylaxis and treatment of Malaria in pregnancy), or ITN (insecticide treated bednets), although the effectiveness
estimate is from ITN alone
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regardless of parity [47] (Table 2). On a country-level,
both ITNs and IPTp are used in combination in en-
demic populations and currently in LiST, the effect of
ITNs is also assumed to apply to women using IPTp.
Therefore, the baseline coverage for ITNs is estimated
from the latest household survey data for “% pregnant
women receiving 2+ doses of Sp/Fansidar during
pregnancy”, or “% pregnant women sleeping under an
insecticide-treated bednet (ITN)” if the former is not
available.
Detection and management of conditions in pregnancy
Syphilis case management
In 2012, there were an estimated 930,000 maternal
syphilis infections worldwide, leading to 350,000
adverse pregnancy outcomes including 143,000 early
fetal deaths and stillbirths [48]. Maternal syphilis in-
fection is able to cross the placenta and infect the
fetus in-utero, which can lead to multi-organ damage
or congenital developmental abnormalities, hence
pregnant women with untreated syphilis infection
have 21% higher rates of fetal loss or stillbirth com-
pared to uninfected women [49].
Detection and treatment of syphilis during pregnancy is
estimated to reduce all-cause stillbirths by 82% (8 studies,
3931 births. RR 0.18, 95% CI 0.10 to 0.33) [50]. Only still-
births in women with untreated syphilis could potentially
benefit from this intervention. The affected fraction is
therefore calculated as the proportion of cases in the
whole population that may be attributed to the exposure
(untreated syphilis), (see Table 3, Additional file 1). This
effect estimate is currently applied only to antepartum
stillbirths.
No robust country-level data for the current (baseline)
coverage of detection and treatment of syphilis in preg-
nancy are available for all countries modelled in LiST.
Testing and treatment of pregnant women is undertaken
during antenatal care visits. As a minimum of two visits
is usually required, one to take the blood test and the
second to receive the result and get the treatment, it is
assumed that a sub-set of those attending full antenatal
care (ANC4+) will receive the intervention. Currently, in
LiST, it is assumed that a proportion of women attend-
ing all four ANC visits in a country will receive testing
and treatment for syphilis, and that none receiving fewer
than 4 visits will receive such services. These levels were
defined by expert opinion, assuming that coverage of the
intervention increases with coverage of four ANC visits,
for example where ANC4 coverage is low (<40%) only
20% of those attending will receive testing and treatment
(Table 3). A limitation of this approach is that the na-
tional level ANC4+ coverage is likely to overestimate the
coverage in women with syphilis who, due to socio-
economic factors, are less likely to access such care than
the general pregnant population. Work is currently un-
derway to examine the validity of these coverage proxy
assumptions in LiST, and to propose methods to im-
prove these coverage estimates.
Diabetes case management
The global epidemic of obesity is affecting pregnancies
worldwide [51], with increasing prevalence of type II
diabetes in women of reproductive age and gestational
diabetes across all regions [52, 53].
Pregnancies affected by gestational diabetes have a
higher risk of perinatal mortality than unaffected pregnan-
cies [54], and pregnant women with pre-existing type I or
II diabetes are at increased risk of stillbirth even in high
income countries (RR 2.9, 95% CI 2.05 to 4.09) [55] .
A review undertaken in 2011 was unable to provide
an appropriate effect estimate for the overall package
of diabetes detection and management in pregnancy,
and hence the effect estimate recommended by the
technical working group was based on a Delphi
process for expert opinion [17]. This estimated a 10% re-
duction in diabetic-related stillbirth with diabetes screen-
ing and management versus no specific identification or
care for women with diabetes [17]. The affected fraction
that could potentially benefit from this intervention are
stillbirths attributable to diabetes (Table 3). No robust
country-level data for the current (baseline) coverage of
diabetes screening and management were available. In
general, coverage of this intervention is thought to be low
and it was therefore assumed, based on expert opinion,
that only a small minority (5%) of women accessing 4 or
more ANC visits would be receiving this intervention. In
practice, this is likely to vary by setting and local policy.
Hypertensive disorders of pregnancy case management
Hypertensive disorders of pregnancy, including pregnancy
induced hypertension, pre-eclampsia and eclampsia, are
common complications which occur and approximately
6% of pregnancies are affected by its more severe forms
(e.g., pre-eclampsia and eclampsia) [56]. In high-income
countries where early detection is possible, women with
either pre-eclampsia or pre-eclampsia have approximately
double the risk of stillbirth or neonatal death compared to
unaffected women [55]. The risks are likely to be higher in
low-resource settings with limited access to detection, and
management which may include emergency caesarean
section.
The risk is highest for those affected by the more
severe forms of hypertensive disorders, and hence cur-
rently in LiST the effect of intervention is modelled only
for these two more severe conditions.
No suitable evidence was found for a package of inter-
ventions for the management of pre-eclampsia and
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eclampsia, and hence the effect estimate recommended
by the technical working group for this intervention was
based on a Delphi process for expert opinion. This
process suggested a 20% reduction in antepartum and
intrapartum stillbirths in women with pre-eclampsia and
eclampsia with a package of management interventions
including antihypertensive, magnesium sulphate and
C-section if needed [16]. The affected fraction is still-
births attributable to pre-eclampsia or eclampsia (see
Table 3). Similar to the case for diabetes, no robust
country-level data for the current (baseline) coverage of
hypertensive disorders management were available, and
coverage of this is thought to be low so it was therefore
assumed, based on expert opinion, that only 5% of
women accessing 4 or more ANC visits would be receiv-
ing this intervention.
There is currently insufficient evidence to estimate the
effect of potential interventions including calcium sup-
plementation (see micronutrient interventions above) or
aspirin [16, 35] to prevent hypertensive disorders of
pregnancy.
Prolonged pregnancy case management
Pregnancies lasting longer than around 42 weeks are as-
sociated with an increased risk of placental failure and
stillbirth. An estimated 14.2% of stillbirths worldwide are
attributable to prolonged pregnancy [1]. Induction of
pregnancy is an effective method to prevent adverse
pregnancy outcomes. A recent Cochrane review was
underpowered to detect an effect on stillbirth reduction
with induction of pregnancy at 41 completed weeks or
more versus expectant management (17 trials, 7407
women. RR 0.30, 95% CI 0.08 to 1.08), however the re-
view found a 69% reduction in perinatal deaths (17 trials,
7407 women. RR 0.31, 95% CI 0.12 to 0.88) [13, 57]. The
effect on all cause perinatal mortality is used for the esti-
mate of effectiveness in LiST. This risk data is consistent
with population-based data from Denmark, where the
risk of fetal death after 42 weeks was reduced by 30–
33% (p < 0.05) with induction of labour for prolonged
pregnancy [58].
The affected fraction that could potentially receive
benefit from this intervention are stillbirths attributable
to prolonged pregnancy. Gulmezoglu et al. estimate that
7.5% of all pregnancies progress beyond term [57]. The
increased risk of stillbirth in post-term pregnancies cur-
rently used in LiST is RR 1.8 [59] (Table 2).
Caution however is required prior to consideration of
scale-up of this intervention. In the absence of both
widespread availability of accurate dating of pregnancies
through early ultrasound and safe emergency obstetric
care, there is real potential for harm to women and their
babies through increased risk of caesarean section and
iatrogenic late preterm or early term (37 weeks gesta-
tion) birth in cases of mistaken gestational age [60]. For
this reason, coverage of this intervention is capped by
default to equal coverage or the proportion of births oc-
curring at Comprehensive Obstetric Care (CEmOC)-
level facilities.
Childbirth care
All pregnant women need access to appropriate child-
birth care, including skilled birth attendance, and timely
access to Basic Emergency Obstetric Care (BEmOC) or
Comprehensive Obstetric Care (CEmOC) if complica-
tions arise [61]. Higher coverage of birth with a skilled
attendant is strongly associated with lower intrapartum
stillbirth rates [1, 62]. Similarly, higher coverage of
caesarean section up to rates of 10% are associated with
sharp reductions in stillbirth rates, although no benefit
of higher rates is seen [63].
Skilled attendance outside BEmOC or CEmOC facilities
All cause stillbirths were estimated to be reduced by
23% (RR 0.77. 95% CI 0.69 to 0.85) for women who de-
livered at home/outside BEmOC or CemOC facilities
with a skilled birth attendant based on a meta-analysis
of 2 before and after studies [19]. A similar estimate of
25% reduction was obtained from a Delphi process [19].
Childbirth care in BEmOC or CEmOC facility
A systematic review of the impact of skilled birth attend-
ance and Emergency Obstetric Care found insufficient
evidence from randomised trials or robust quasi-
experimental designs to provide an estimate of effect for
Emergency Obstetric Care. The estimates of effect for
these interventions were therefore obtained through a
Delphi expert opinion process [19] which determined
that 45 and 75% of intrapartum stillbirths could be
prevented by universal access to BEmOC and CEmOC
respectively, compared to home delivery without a
skilled attendant.
For all of these childbirth care interventions, the af-
fected fraction is all intrapartum stillbirths. The coverage
of these three packages of care is interconnected – with
the sum of coverage for each of the three packages, plus
those delivering at home without a skilled attendant,
summing to 100%. The baseline coverage of skilled birth
attendance is drawn from data collected during recent
household surveys. No suitable data are available to esti-
mate the coverage of emergency obstetric care packages,
and hence the baseline estimates of coverage are based
upon expert opinion, which assumes a relationship
between level of facility delivery and the proportion of
women able to access emergency obstetric care packages
at those levels of care (Table 2).
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Discussion
In this section we provide details about the limitations of
the current approach, alongside details of other potential
refinements to strengthen the modelling of the effects of
interventions on stillbirths in LiST to further improve its
utility to policy makers and program managers.
Limitations of current approach and recommendations
for future improvements
Underlying data to support modelling and estimation for
stillbirths are not as strong as for other maternal-child
outcomes. Advances have been made in the overall
quantity of data to inform country-level estimates of
overall stillbirth rates, however as stillbirth and neonatal
deaths are modelled independently as separate outcomes
within LiST, misclassification between intrapartum still-
birth and early neonatal death, thought to remain com-
mon in low-resource settings, may potentially effect the
accuracy of the estimates [26]. In addition, the quality of
data available to inform the breakdown of stillbirths by
timing (antepartum/ intrapartum) remains low [1].
Prevalence data used to calculate the attributable stillbirth
mortality currently included are generally based on single
time-point data that were available around the year 2010.
Since this time, an increase in the measurement and
reporting of prevalence data, coupled with improvements
in estimation techniques have resulted in improved
country-level estimates which could be incorporated into
future LiST versions.
The prevalence of specific exposures and stillbirth risk
factors may be expected to vary over time in a given
country but data are not available to reliably track these
trends over time. For most interventions in LiST, these
factors are assumed to remain static when estimating
maternal, neonatal, or child outcomes with the exception
of certain pathogen-related illnesses (e.g. diarrheoa,
pneumonia, and meningitis) which shift as certain inter-
ventions are scaled up and the etiological burden
changes accordingly.
Issues that have been identified with the application of
some effect estimates (e.g. folic acid supplementation
and fetal growth restriction) have now been addressed.
However, data underpinning the effectiveness estimates
remains sparse for some interventions. In some cases,
effectiveness data must be drawn from trials conducted
in high-income countries and in others, where the con-
duct of randomized controlled trials (RCTs) would not
be ethical, estimates are derived from expert opinion.
In addition to this, effectiveness estimates, apart from
childbirth care, remain broadly applicable to all still-
births, and are not time-specific (antepartum/ intrapar-
tum). The current approach assumes that this estimate
of affect is equally applicable to all ‘affected’ antepartum
stillbirths and intrapartum stillbirths, apart from for
syphilis detection and treatment and malaria prevention.
However, in practice this is unlikely for many conditions.
For example, the effect of micronutrient supplementa-
tion is likely to primarily effect antepartum stillbirths. A
future approach could consider modelling all stillbirths
together and for childbirth care interventions, the per-
centage of intrapartum stillbirths could be applied as the
affected fraction. However, a limitation of this is that the
number of averted stillbirths split by timing (antepartum
versus intrapartum) would no longer be available to
guide policy makers. Further research is required to
understand how widespread the use of these data are by
programs and policy makers.
Reliable population-based coverage data are not avail-
able for many interventions. LiST has therefore relied on
expert opinion to estimate likely levels of coverage for
interventions using different levels of coverage reported
for antenatal and childbirth care as a proxy. The current
assumptions create a step-like increase in coverage for
some interventions, such as the detection and manage-
ment of syphilis and childbirth care, whilst very low
coverage is assumed for others, such as the detection
and management of diabetes and hypertension, even at
high ANC4 coverage (see Additional file 3: Figures S1
and S2). New evidence is emerging and may help to in-
form these coverage assumptions. For example, national
estimates of coverage for testing and treatment for syph-
ilis during pregnancy are now available and reveal poor
correlation with ANC4 coverage (see Additional file 3:
Figure S3) [48]. Work is underway to review currently
available evidence to guide these coverage estimates and
refine these assumptions in future versions of LiST.
Quantification to estimate the number of lives saved
involves some degree of uncertainty. This uncertainty
has not been quantified up to now, however initial work
has been completed to provide an accompanying range
of upper and lower bounds for all model outcomes. In
future versions of LiST where these ranges are standard
outputs, parameters which would influence the uncer-
tainty ranges for stillbirth outcomes include the effect-
iveness of stillbirth interventions, stillbirth rates, and the
proportion of stillbirths that occur antepartum versus
intrapartum. After adequate rounds of beta testing,
uncertainty estimates will be available as ranges for still-
birth rates, the number of stillbirths, and the number of
stillbirths prevented as estimated by LiST. A full descrip-
tion of the model’s methodology for uncertainty and
sensitivity analysis is forthcoming and will be presented
in a peer-reviewed publication.
Updates to effectiveness data for currently reviewed
interventions
We undertook a review of the existing literature for the
included interventions and searched for any newer
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evidence published after the previous reviews. No subse-
quent publications relating the estimate of effect for de-
tection and treatment of syphilis, childbirth care or
management of prolonged pregnancy were found.
For detection of fetal growth restriction, a new review
found no evidence of benefit for perinatal mortality with
symphysis fundal height and serial ultrasound scans
compared to clinical palpation alone (1 study. 1639
women. RR 1.25, 95% CI 0.38 to 4.07) [64]. A further
new review also found no evidence for biochemical tests
of placental function on perinatal mortality (2 trials. 740
women. RR 0.88, 95% CI 0.36 to 2.12) [65]. However,
potentially more promising as an intervention to prevent
stillbirth is the possible effectiveness of detection and
monitoring of women at high-risk of fetal growth re-
striction [66]. This should be considered for inclusion in
future versions of LiST if further evidence applicable to
the low and middle income setting becomes available.
There has been a proliferation of studies examining in-
terventions to improve outcomes for diabetes, particu-
larly gestational diabetes, and hypertensive disorders of
pregnancy. A full update is now warranted and the pre-
viously undertaken systematic reviews on this topic
would be bolstered by adding further evidence to sup-
port the effect estimate used in LiST [16, 17].
Evidence to support the addition of other potential
interventions to prevent stillbirths
Whilst a plethora of evidence summaries have been pub-
lished in the last 5 years relating to interventions during
pregnancy which may improve stillbirth outcomes, the
majority of these studies found no evidence of effect or
pertain to interventions which could not be readily
scaled-up in low resource settings. In the future it would
be desirable to improve the utility of the LiST tool for
stillbirths by expanding the tool to include additional in-
terventions targeting major risk factors for or causes of
stillbirth. Below we detail some candidate interventions
for possible inclusion:
Fetal growth restriction case management
Fetal growth restriction, which is frequently due to pla-
cental dysfunction, is a common final pathway leading
to stillbirth in many cases (Fig. 2). Reliable detection of a
fetus whose growth is faltering can allow close monitor-
ing and timely induction of labour or caesarean section
prior to fetal death. A package for screening which relies
upon body-mass-index (BMI), fundal height and tar-
geted ultrasound scan with appropriate management
was estimated by Delphi expert consensus to reduce
antepartum and intrapartum stillbirths in high risk
pregnancies by 20% [15]. This effect would require the
availability of specialised obstetric services including
serial ultrasound scans and caesarean section if needed,
which are not routinely available in many settings. This
effect was included in the LiST model from 2011 to
2016. However, it is currently not included as both the
screening package and potential effectiveness in different
settings is poorly defined.
Nutritional interventions
The last few years have seen the increasing roll out of
folic acid fortification to prevent folate-sensitive neural
tube disorders [67]. Although previous versions of LiST
included an estimate of effect for folic supplementation,
research has shown supplementation to be an ineffective
strategy, because in most cases, even when taken, sup-
plements are not taken peri-conceptually, and hence
started too late to be effective to prevent neural tube de-
fects and associated stillbirths. Folic acid fortification is
estimated to reduce primary neural tube defects by 41%
(11 studies. RR 0.59, 95% CI 0.52 to 0.68) [14], and as-
suming fortification does not alter the spectrum of the
severity or stillbirth rates amongst affected foetuses, it
would be expected that stillbirths attributable to neural-
tube defects would also decrease by 41%.
Maternal overweight and obesity are associated with
an increased risk of stillbirth, preterm birth, congenital
abnormalities, poor fetal growth and low birthweight
[55, 68]. Ten percent of stillbirths globally are estimated
to be attributable to maternal obesity [1]. To date, there
is limited evidence to inform interventions to reduce
maternal obesity, either pre-conception or during preg-
nancy, to improve stillbirth outcomes [69, 70]. This re-
mains an important area for future research to improve
the understanding of the biological pathways to increase
risk, and which interventions may be amenable to clin-
ical interventions.
Fertility/ Family planning interventions
The positive effects of contraception on maternal,
newborn and child health have been well-documented
[71]. Extremes of maternal age are associated with in-
creased risk of stillbirth. Globally 6.7% of all stillbirths
are estimated to be attributable to older maternal age
(>35 years) [1]. Adolescent pregnancy is also associated
with increased risk, especially for girls under 16 years of
age [72], but the magnitude of risk has not yet been quan-
tified as studies frequently include these high risk groups
with those 19–20 years who have the lowest biological
risk. Short inter-pregnancy intervals are associated with
poor perinatal outcomes, however the effect on stillbirths
has yet to be quantified [73]. To date, there is insufficient
evidence to support the inclusion of family planning inter-
ventions to reduce stillbirths in LiST. Currently, modelling
stillbirths in LiST does not capture these effects as
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explained above. Moving forward and as the evidence base
increases, inclusion of the potential effects of interven-
tions such as reducing births in girls under 18 years of
age, improved inter-pregnancy spacing and reducing
unplanned pregnancies would be useful to planners and
policy makers as they consider the potential full-impacts
of their family planning programs.
Environmental and lifestyle interventions
Smoking is associated with an increased risk of stillbirth
[74]. Worldwide smoking has been estimated to be at-
tributable for 1.1% of stillbirths worldwide. Unless the
trend of increasing rates of smoking among women in
low- and middle-income countries (LMICs), especially
in South America and parts of Asia, is reversed, smoking
will likely become an important cause of preventable
stillbirths in these regions [75]. Research has shown that
pharmacological and psychosocial interventions can in-
crease smoking cessation in pregnant women, however
no effect has been shown on stillbirth rates, and these
interventions are expensive and currently remain im-
practical in most high-burden settings [76, 77].
Household air pollution (HAP) exposure is known to
be associated with multiple adverse health outcomes and
increased mortality. Exposure is associated with an in-
creased risk of stillbirth [78, 79]. Based on comparing
stillbirth risk in observational studies of populations with
low versus high HAP exposure, it is estimated that inter-
ventions to reduce HAP exposure could reduce still-
births by 34% (OR 0.66, 95% CI 0.54 to 0.81) [79]. In
recent years, multiple studies have assessed interventions
to reduce HAP and although the majority have shown
effectiveness in reducing HAP levels, the declines have
not reached the levels as recommended by the World
Health Organization [80].
Violence against women, which remains highly preva-
lent worldwide, is associated with increased risk of still-
birth [81]. Although 30% of ever-partnered women
report having experienced sexual or physical violence,
no specific estimates are available for pregnant women
[82]. There is some evidence to suggest that advocacy
interventions which aim to reduce exposure to violence
may produce benefits [83], however, insufficient evi-
dence is available to estimate the effectiveness of such
interventions to reduce exposure and stillbirth rates as a
result.
Prevention of Rhesus disease
Around 1% of stillbirths worldwide are estimated to be
attributable to Rhesus (Rh) disease [1]. Antenatal screen-
ing for Rh negativity and anti-D immunoglobulin has
been highly successful in reducing the incidence of
haemolytic disease of the fetus and newborn and reducing
stillbirths in countries where it has been implemented
[84]. Anti-D has been shown to reduce iso-immunisation
[85]. Whilst there is currently insufficient direct evidence
to estimate the effectiveness of this intervention on still-
births [85], the indirect evidence could be considered and
may be used to inform future versions of LiST, especially
for settings with high prevalence of Rh negativity and ad-
equately strong health systems.
Detection and management of HIV in pregnancy
A recent review estimated that 0.7% of stillbirths in sub-
Saharan Africa may be attributable to HIV infection [1],
however the limitations of these data are noted. Roll-out
of antiretroviral treatment (ART) to reduce the risk of
mother-to-child transmission of HIV infection and the
increased uptake of universal provision of maternal ART,
in particular, are likely to affect this subgroup of still-
births. However, as the attributable fraction of stillbirths
that would benefit from this intervention is small and
data to support the effect of ART on reduction in still-
birth risk are sparse, this intervention is not currently
modelled in LiST.
Modelling using stillbirth cause of death or risk data
As detailed above, no comparable country-level cause-
specific stillbirth mortality estimates are currently avail-
able for most countries. The World Health Organization
has recently published ICD-PM, the application of ICD-
10 to perinatal deaths in which it seeks to improve the
data availability and comparability for perinatal deaths,
including stillbirths, across countries [86]. However, it is
likely to be many years before such data are readily avail-
able of sufficiently high quality across countries from all
regions worldwide to allow global and country-level still-
birth cause-of-death estimates. Even in high-income regions
with access and resources to conduct sophisticated investi-
gations, the cause of stillbirth is unknown in around 30% of
cases [2]. Hence, updating and extending the approach of
using the attributable mortality as the affected fraction to
further interventions remains the most feasible approach at
present.
Conclusions
LiST is a widely-used and valuable tool for modelling
the impact of scaling-up interventions to reduce still-
births across high-burden settings. Previous iterations of
LiST have been hampered by a lack of robust data for
some of the estimates of effectiveness, attributable mor-
tality and coverage. Data for stillbirths remain incom-
plete but are improving and going forward, the LiST
model will continue to evolve to reflect the improving
data and expanded evidence base in order to provide an
increasingly reliable tool for policy and programming
purposes.
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